Tag Archives: EHA

EHA 2018 and Things to Do while in Stockholm

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

“The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.”

EHA’s Annual Congress has a program that tackles every subspecialty in hematology and offers attendees the opportunity to network with experts from all corners of the world. Apart from the educational and scientific program that uncovers the latest findings in hematology, the congress also provides attendees with the opportunity to attend satellite programs and to visit the exhibition put together by well-known pharma companies.

The 23rd Congress of EHA will take place in Stockholm between 14-17 June 2018.

Book your accommodation for EHA 2018.


Stockholm at a glance

The name Stockholm comes from the words “stock” meaning “log” and holm meaning “islet.” Stockholm is built on 14 islands connected by 57 bridges. Over 70 museums are spread across the city, covering an interesting mix of topics and attractions and showcasing the city’s heritage. On the shortest day, Stockholm’s inhabitants see only six hours of sunlight, while on the longest day they enjoy up to 21 hours.


Gamla Stan


Gamla Stan is where the capital was founded in 1252 and it currently represents one of the best preserved medieval city centres in Europe. In Stockholm’s Old Town, the cobblestone streets are reserved for pedestrians only. Even now cellar vaults and frescoes from the Middle Ages can be found behind the visible facades.

In Gamla Stan, you can visit several churches and museums including Sweden’s national cathedral Stockholm Cathedral and the Nobel Museum. Of course, one of the main attraction is t is the Royal Palace, one of the largest palaces in the world with over 600 rooms. Attending the parade of soldiers and the daily changing of the guard is something you’ll definitely like!




Located on Royal Djurgården, Skansen is the first open-air museum in the world. Its 150 buildings tell Sweden’s story from the past 500 years. Some say that Skansen is Sweden in miniature. Swedish traditions such as Midsummer, Walpurgis Night and Lucia are celebrated at Skansen.

The museum attracts more than 1.3 million visitors each year. One of the top attractions is the full replica of an average 19th-century town. The great part is that you’ll even see craftsmen in traditional dress such a shoemakers, bakers, etc. showcase their skills as if time has stopped.

The open-air zoo boasts a large number of Scandinavian animals including the bison, brown bear, moose, grey seal, lynx, otter, red fox, reindeer, wolf, etc.


The Vasa Museum


This maritime museum in Stockholm is famous worldwide because it is where you can see the warship Vasa, the only almost fully intact 17th century ship in the whole world. The Vasa sank in 1628 in Stockholm and was raised from the seabed 333 years later. The Vasa Museum opened in 1990 and it is said to be the most visited museum in Scandinavia.


The ABBA Museum

This is definitely a must-see for music fans out there. The museum opened in 2013 and is actually an interactive exhibition about the pop band, following its history from folk singers to music icons. The interactive elements include performing on stage with the band and mixing a studio recording.


Book your accommodation for EHA 2018.

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

All You Need to Know about The European Hematology Association and its Annual Congress

The European Hematology Association (EHA) was founded in Belgium in 1992. For the next 6 years, the Association organised a congress in different European cities every two years. Starting 1998, the congress became an annual event taking place in June. Nowadays, the Association’s executive office is located in the Netherlands, with over 3,200 members from 100 countries.

The educational program of the annual congress is based on the European Hematology Curriculum, the main goal of the Association being to lobby for hematology and promote research that supports hematologists in- and outside Europe.

Is the Annual Congress of the European Hematology Association on your list in 2017 or/ and 2018? Give us a sign and we’ll handle your accommodation needs in a fast and reliable way!

For 2017.

For 2018.


The Annual Congress

At the EHA Annual Congress, hematologists and affiliated professionals gain access to original unpublished data and ideas regarding hematological innovation. During the congress, they will be able to improve their knowledge and approach regarding evidence-based diagnosis and treatment diseases related to hematology, access research results on hematologic disorders, gain insight about innovative techniques and diagnostic tools, as well as leverage networking opportunities with other medical professionals, patient groups, medical industry and the media.

Besides a program that covers every subspecialty in hematology, the Annual EHA Congress gives attendees the opportunity to network with experts from across the globe. The congress also provides the opportunity to attend satellite programs, updates-in-hematology and to visit the exhibition put together by big pharmaceutical companies.

Between 22-25 June 2017, the EHA is organizing its annual congress in Madrid, Spain. The program will cover 15 tracks as follows: advocacy track, benign hematology, biology, clinical, early career track, general skills, laboratory diagnosis, lymphoid malignancies and plasma cell disorders, myeloid malignancies, pediatric hematology, personalised medicine, stem cell transplantation and special therapy, thrombosis and hemostasis, transfusion medicine, and translational. For a more detailed breakdown of each track, visit this page on their website.

There are 17 sessions that will be covered during this year’s annual congress: basic science in focus, clinical debate, early career session, education session, hematology-in-focus, joint symposium, laboratory diagnosis workshop, late breaking abstracts, meet-the-expert, molecular hemopoiesis workshop, oral presentation, plenary session, poster session, presidential symposium, satellite symposium, scientific working group, special session.

Make sure you know the key dates and other important information.

In 2018, the annual congress will take place in Stockholm, Sweden, between 14-17 June.

Apart from the annual congress, EHA also hosts other significant events meant to support hematologists and improve patient care.


Educational Events

Throughout the year, EHA organizes educational courses on the latest developments in hematology. These fall under two main categories: hematology tutorials and highlights of past EHA. In 2017, there is a tutorial on Lymphoid Malignancies in Warsaw, Poland, between 17-18 March and one on Laboratory Hematology between 8-9 April in Çanakkale, Turkey.

The Highlights of Past EHA event will take place in Cairo, Egypt, between 14-16 September 2017. This year, EHA-HOPE, short for Highlights of Past EHA, aims to bring the key messages from various fields of hematology of the 22nd Congress of EHA to the Middle East and North Africa.


Scientific Events

The EHA-SWG Scientific Meetings represent a joint collaboration between the EHA Scientific Working Groups (SWGs) and EHA. The meetings aim to provide an innovative format that includes e.g. discussions with patient organizations, regulators and pharma companies.

In 2017, there will be 4 big scientific meetings:

  • The EHA-SWG Scientific Meeting on Rare Lymphomas between 10-12 March, in Barcelona, Spain.
  • The EHA-SWG Scientific Meeting on Aging and Hematology.
  • The EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms between 12-14 October, 2017.
  • EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy between 23-25 November, 2017.

Contact us for a personalised accommodation offer for the Annual Congress of the European Hematology Association. No strings attached. We usually reply within a few hours.

For 2017.

For 2018.


Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses, regardless of their location.

Top Trends that Will Dominate the Pharma Sector in 2017

We’re soon saying goodbye to 2016, a bustling year for pharma in terms of technology, innovations, as well as mergers and acquisitions. Big companies saw important breakthroughs, new drugs have been approved by the FDA and important lawsuits have been gained. All in all, an exciting year for the pharma and healthcare industry.


Now is the time to look at 2016 and understand which important trends from 2016 will pick up next year and what their influence will be.


Drug prices will still be heavily debated

Drug prices have made headlines over the past few years (they were even an election issue in the US) and will continue to do so throughout 2017.

Dr. Carole Bruckler, Senior Advisor at Allied World Healthcare, predicted that “2017 will be a year where ongoing trends will crystalize further,” and that  “in the US, there is clear political will forming against annual or quarterly drug price increases to fuel sales growth.”

Although a Clinton victory would have meant high drug prices, Donald Trump’s election in the US doesn’t mean that the pharma industry is out of hot water yet. His plans to have uniform pricing schemes could highly impact profit margins and may even mean a change in pharma’s existing business models.


Patients will hold the power

It seems that those days when patients would go to the doctor whenever they got sick to have medication prescribed are gone. Nowadays, patients are empowered. They have access to huge amounts of information online and can learn about their health conditions. When dealing with mild symptoms, they can even use the information that they find to choose from various treatment alternatives. This means that, in many instances, doctors cannot influence patients’ choices anymore. Therefore, pharma companies have to start looking for new ways to get their medications sold.

When it comes to empowered patients, pharma and healthcare companies need to understand that, thanks to technology and the opportunities it provides, their expectations are high. If they are not provided with an immediate solution, they know they always have an alternative.

Smartwatches like Apple Watch or Samsung Gear and fitness bands (FitBit, Jawbone, Garmin) have sensors capable of taking biometric readings. As they become more advanced, wearable devices will become a key asset in gathering clinical trial data remotely in real-time but also in helping patients monitor their health without the need for a doctor or nurse.


Tech giants are here to stay

Over the past few years, pharma companies have witnessed the entry and involvement of

tech companies such as Google, Apple and IBM. The latter can help collect and process massive amounts of health-related, thus helping pharma companies gain a better understanding of diseases, broaden their R&D strategies and find the right treatments.

Google’s Alphabet hosts several separate firms, including Google Ventures, Google X and Calico. All three of them are focusing on drug development. Calico tackles aging-related diseases such as Alzheimer’s, and Google Ventures increased its funding of healthcare-related ventures. Not to be left out is Google’s partnership with Novartis to develop “smart contacts” for age-related degeneration in eyesight.

Meanwhile, IBM and Apple have teamed up with Medtronic and Johnson & Johnson to carefully leverage clinical trial data to create better targeted therapies for patients, while ensuring the latter’s compliance with their drugs. Apple’s HealthKit and ResearchKit technologies are complementing such partnerships, as is IBM’s supercomputer Watson.


Artificial intelligence might become a game changer in the near future

Using the power of AI and supercomputers for medical decision making purposes will definitely change everyday medicine. Cognitive computing platforms such as IBM Watson have the capabilities to interact in natural language, process vast amounts of Big Data and understand patterns and insights while learning from each interaction. By digesting and interpreting millions of pages of scientific literature, IBM Watson can assist pharma companies in the development of new drugs while repurposing existing ones.

The fact that cognitive computers have been used to analyse big data, not only in genomic research but also in biotechnology, might change the way new drugs are found. The era of human experimentation might come to an end and be replaced by the era of detailed simulation of human physiology. Instead of being tested on people, drugs could be tested by supercomputers on billions of simulations modelling the physiology of the human body in a matter of seconds. This won’t happen in 2017 since it’s much too soon but it’s something that pharma should support and look into throughout the next couple of years.

These were our top picks for trends that will continue to dominate the pharma sector in 2017 and beyond. Of course, they are not set in stone. As technology advances, many great things and innovations will emerge.


Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

From 60 Pharma companies to 10 Big Pharma companies in 20 Years

We’ve all heard about Novartis, Pfizer, Sanofi and Roche. They’re some of the big guys in the pharma landscape, enjoying increased popularity, splitting the high budgets and revolutionizing the healthcare and pharma industry but what’s the road they took to get here? In order to answer that question, we’re going to analyze the 10 biggest pharma companies nowadays which used to be around 60 distinct companies 20 years ago. Here’s what they did to stand the test of time and grow.



It all dates back to 1970 when Ciba-Geigy was formed by the merger of J. R. Geigy Ltd and CIBA. In 1996, from the merger of Ciba-Geigy and Sandoz Laboratories, Novartis was born. In 2005, Novartis acquired Hexal and Eon Labs, thus growing its generic division Sandoz. A year later, in 2006, Novartis acquired full control of Chiron Corp. for USD 5.1 billion. In 2010, Novartis acquired the world’s largest eye-care company Alcon for USD 39.3 billion. Three years later, in 2012, the company bought Fougera Pharmaceuticals for USD 1.5 billion. In 2016, Novartis acquired Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD).

AstraZeneca (AZ)

AstraZeneca  was created in 1999 following the merger of Astra and Zeneca Group. In 2004, AZ completed its first big acquisition of Cambridge Antibody Technology. Later on, in 2007, it acquired MedImmune for about USD 15.2 billion. In 2012, AstraZeneca acquired Ardea Biosciences for USD 1.3 billion. One year later, it acquired Amylin from BMS for USD 4.3 billion and in 2015 acquired ZS Pharma for USD 2.7 billion. In 2015, AstraZeneca bought 55% majority stake in Acerta for USD 4 billion.


In 2000, Pfizer acquired American pharmaceutical company Warner–Lambert for USD 111.8 billion to bring its drug, Lipitor, to market. In 2002, Pfizer aimed to acquire full rights to Pharmacia’s product Celebrex and thus agreed to buy Pharmacia for stock valued at USD 60.0 billion. In 2009, Pfizer bought pharmaceutical company Wyeth for USD 68.0 billion. In 2015, Pfizer acquired Hospira for USD 15.2 billion and announced the merger with Allergan. The latter is considered to be one of the biggest mergers in pharma history. In 2016, Pfizer announced the successful completion of its acquisition of Medivation.


Sanofi resulted from the merger between Sanofi-Synthélabo and Aventis in 2004. The former was created in 1999 when Sanofi merged with Synthélabo. Aventis was formed in 1999 following the merger of Rhône-Poulenc S.A. with Hoechst Marion Roussel (HMR). The latter itself was formed in 1995 from the merger of Hoechst AG with Cassella, Roussel Uclaf and Marion Merrell Dow.

In 2011, Sanofi-Aventis acquired Genzyme and changed its name to Sanofi.

Johnson & Johnson

J&J was founded in 1886 as a medical devices, pharmaceutical and consumer packaged goods company. The pharmaceutical division is made up of Janssen & Cilag. In 2006, Janssen acquired the consumer healthcare business of Pfizer for USD 16.6 billion in what is considered to be the company’s largest M&A deals. In 2013, the company acquired Aragon Pharma and in 2014 it bought Alios BioPharma, Inc. for USD 1.75 billion.

Merck & Co.

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Merck & Co. was established as a subsidiary of Merck in 1891, but became an independent company in 1917. It is known as MSD (Merck Sharp and Dohme) outside of North America. In 1993, Merck purchased Medco Containment Services Inc. for USD 6 billion. In 2009, Merck merged with Schering-Plough. The latter had acquired Organon from Akzo Nobel in 2007 while Organon resulted from a merger between Diosynth and Organon in 2004. Ten years later, Merck bought Cubist Pharmaceuticals for USD 8.4 billion.


Roche’s first acquisition took place in 1994 when the company bought Syntex Corporation for USD 5.3 billion. In 2002, Roche’s Japanese subsidiary Nippon Roche merged with Chugai. Following the deal, Roche got a majority stake in the Japanese company. In 2008, Roche acquired Ventana Medical Systems for USD 3.4 billion and in 2009, the company bought Genentech for USD 46.8 billion.


Teva resulted from the merger between Assia, Zori and Teva in 1976. In 2006, Teva completed its first big acquisition of IVAX Corporation for USD 7.4 billion. In 2011, it acquired Cephalon for USD 6.8 billion. After acquiring Auspex Pharma for USD 3.5 billion in 2015, Teva completed its acquisition of Allergan’s generics business (“Actavis Generics”) in 2016.

Gilead Sciences

Gilead Sciences was founded in June 1987. Over the past 16 years, the company has made several acquisitions. The biggest ones include: CV Therapeutics for USD 1.4 billion in 2009 and USD 10.4 billion acquisition of Pharmasset in 2011.

GlaxoSmithKline (GSK)

GSK was founded in 2000 following the merger of Glaxo Wellcome and SmithKline Beecham. In 2001, GSK acquired Block Drug for USD 1.2 billion. In 2009, GSK acquired Stiefel Laboratories for USD 3.6 bn. 4 years later, in 2013, GSK acquired Human Genome Sciences (HGS) for USD 3 billion. In 2015, GSK completed the acquisition of vaccine business of Novartis and sale of its oncology business to the Swiss drug major in a global deal. Under the agreement, GSK Pharma expanded its vaccine portfolio and took over 120 employees from Novartis to boost its sales in India.

There’s so much pharma history behind all of the big names out there and the evolution is far from reaching an end. We’re looking forward to seeing what these pharma giants have in store during the next couple of years and who’s going to lead the way in the M&A sector.

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

Could Chatbots Be the Future of Healthcare?

Over the past few years we’ve seen more and more companies invest in mHealth sensors and applications in an attempt to boost medication adherence, enable self-reporting of symptoms and telemedicine consults, etc. While some studies show that there is promise in mHealth apps, others don’t see them as a disruptor for the healthcare industry, which would make the scalability of such technologies very slow.

Smart phones and medical icons

So what’s the underlying cause for the low to mediocre performance of mHealth apps?

Most probably, the answer lies in the lack of a truly engaging user experience. Imagine using an app for health purposes: you first need to install it, then remember to open it daily, fact that will definitely not be entertaining but rather sad given that it will remind you of your illness.

Since nowadays nearly everyone uses mobile messaging apps to communicate with friends and family, it’s becoming obvious that interacting with users directly inside of those messaging apps is much more effective as opposed to asking them to use standalone apps.

This is where chatbots enter the healthcare scene.


From Plain Robots to Doctors in Your Pocket

The doctor-patient relationship is more or less the same as it was 2000 years ago. The technology is much more advances but the process is the same. Patients feel sick, go to the hospital, explain how they’re feeling or where it hurts. Doctors check vitals, ask several questions, offer a diagnosis, and write a prescription.

The nasty part is when doctors are extremely busy and patients become impatient. They search on the internet, read forums, diagnose themselves and oftentimes end up taking the wrong medications. Of course, not all symptoms require an immediate visit to the doctor but it would be good to know when they do and when they don’t.

Using robots to diagnose patients is not as new an idea as you may think. ELIZA, was the world’s first chatbot and it was created 50 years ago with the purpose of being a Rogerian psychotherapist who can chat with patients by reflecting on what they said.

More recently, ProjectRED developed a robotic nurse called Louise, who can talk to patients to go over their medications and home care items when they get discharged from the hospital.

However, if it weren’t for the recent advances in AI, these chatbots would feel more like robots and would face the fate that standalone mHealth apps have had to face.

With artificial intelligence, almost unbelievable scenarios become possible. Imagine your smartphone rings and it’s a chatbot asking you if you still have that soar throat from yesterday and if you’d like to book a doctor’s appointment for the coming day.

Healthcare may see the greatest transformation of all the fields that artificial intelligence will disrupt in the coming years. Its influence on the industry will be broad and deep. Thanks to advanced image-recognition algorithms, diseases can be detected at an incredible speed and accuracy.


Chatbots that Have Already Prompted Big Healthcare Changes

Several companies have already begun using chatbots to redefine the role of the doctor and reposition the patient in relation to his/ her own health.

London-based digital health startups Your.MD and Babylon Health are fixing healthcare systems by cutting down on unnecessary doctor visits. Your.MD’s AI-powered chatbot engages patients just like a physician. The chatbot (your personal health assistant) uses machine-learning algorithms and natural-language processing to understand and engage its users.

MedWhat is another AI-powered medical assistant that can answer questions, such as drug side effects, in a chat format.

Chinese search engine Baidu launched “Melody”, a chatbot that uses artificial intelligence with the aim of helping patients determine whether or not they should see a doctor in person.

Melody integrates with the Baidu Doctor app, it asks the patient preliminary questions and pulls data from digitized textbooks, research papers, online forums and other healthcare sources.

With HealthTap’s bot, users can type a question into Facebook Messenger and receive replies from doctors. Users are also able to see responses from doctors to questions that are similar to their own.

Since we’re pretty sure that this is only the beginning, we expect to see a lot more activity from companies in the healthcare space and not only in the following months. Chatbots won’t replace doctors but they can improve the system, boost medication adherence and contribute to a better health.

Interested in finding out more about pharma, healthcare and tech? Book your accommodation in time for the following events in 2017:

3 Tech Trends that Will Shape the Pharma Industry

There are many things happening in the pharma and healthcare industry. As we’ve discussed in a previous article, chatbots, mHealth sensor, 3D printing and artificial intelligence are impacting every sector of our lives and every industry, pharma making no exception to the rule.

So what is the next gamechanger for the pharmaceutical industry in terms of technology or better yet, what are the technologies that are set to change the industry and shake its core?


Big Data

Big data gives pharma and healthcare organizations the opportunity to use advanced analytics to create patient centricity in their operations and deliver measurable improvements in outcomes. Nowadays, electronic medical record (EMR) data is combined with genomic and genetic data, as well as with financial data and patient-reported data to ensure that the best therapies are delivered to patients.

Apart from healthcare organizations, pharma companies could also leverage Big data to improve areas related to drug development through the provision of compelling evidence of a drug’s benefits.

Big data and the analytics that go with it have the power to revolutionize pharmaceutical R&D, as McKinsey&Company explain in one of their articles. With Big data, the following could be possible (some of them even are!): patients could enroll in clinical trials based on their online activity and not only on their visits to the doctor, trials are monitored in real time, data flows seamlessly between discovery and clinical development, to external partners (physicians and contract research organizations), etc.

Although there are still many challenges ahead in what concerns the use of Big data by pharma companies (organizational silos is only one of them), the benefits are real, especially in the area of R&D.


Cloud Computing

Pharma companies are in the process of changing their business models and leveraging new technologies to cope with demand but also to differentiate themselves. In this context,

many are turning to cloud technology. The latter not only gives them on-demand scalability but also enhanced agility so that they can meet the market demands in a timely manner.

When it comes to R&D, the process is a lengthy one: only about 1 in every 5,000 drugs ever reaches the market and it often takes at least 10 years to develop it. As you can imagine, the costs are tremendous! Given this, cloud technology helps pharma companies process huge amounts of data they deal with as a part of R&D, and replace the information silos that have been formed as a result of legacy infrastructure.

In terms of scalability, given that SaaS computing enables companies to use the services they need regardless of location or device, teams can quickly be scaled up or down depending on the project/ research.

According to a forecast by MarketsandMarkets, the clinical trial market is expected to grow at a CAPGR of 11.5% from 2016 to 2021. Thanks to cloud-based infrastructure, data, including lab, imagery and statistical analysis data, can be delivered quickly and efficiently.


Tech giants have set their eyes on pharma

Apple, Google and IBM have become major players in the healthcare game by closing deals with biopharma companies over the past years.

In August 2015, Google announced a restructure into a holding company dubbed Alphabet that hosts several separate firms, including Google Ventures, Google X and Calico. All three of them are focusing on drug development. Calico tackles aging-related diseases such as Alzheimer’s, and Google Ventures increased its funding of healthcare-related ventures. Not to be left out is Google’s partnership with Novartis to develop “smart contacts” for age-related degeneration in eyesight.

Meanwhile, IBM and Apple have teamed up with Medtronic and Johnson & Johnson to carefully leverage clinical trial data to create better targeted therapies for patients, while ensuring the latter’s compliance with their drugs. Apple’s HealthKit and ResearchKit technologies are complementing such partnerships, as is IBM’s supercomputer Watson.

These are only 3 of the technologies that promise to shape the pharma industry in the upcoming years. Of course, as technology advances, so do security breaches. Therefore, while investing in doing more with the right technology, pharma companies should keep in mind to also make processes safer from a security standpoint so that neither them nor patients face any risks.

Interested in finding out more about pharma and tech? Book your accommodation in time for the following BIG events  in 2017:

  1. EASL 2017 Amsterdam, 19.- 23. April, 2017 -> http://bit.ly/2dXPoBA
  2. EULAR 2017 Madrid, 14.- 17. June, 2017 -> http://bit.ly/2dhJ1rq
  3. EHA 2017 Madrid, 22.- 25. June, 2017 -> http://bit.ly/2e8TX7y